Pharmaceutical Industry 18 – 24 May: Ft Novo Nordisk and Enterprise Therapeutics
- Novo Nordisk has presented new OASIS 4 sub-analyses at ECO2026, showing strong weight loss and mobility improvements from oral semaglutide 25mg tablets.
- Enterprise Therapeutics has reported positive phase 2 results for ETD001, an investigational inhaled ENaC blocker for people with cystic fibrosis who do not benefit from CFTR modulators.
Novo Nordisk Strengthens the Case for Oral Obesity Treatments
Novo Nordisk has presented fresh sub-analyses from the phase 3 OASIS 4 trial at ECO2026, adding further weight to the potential role of oral semaglutide 25mg tablets in obesity management.
The new findings showed that adults living with obesity who received semaglutide tablets experienced substantial weight loss when compared with placebo.
Importantly, the results also highlighted that treatment response should not be viewed too narrowly or too early, as both early responders and non-early responders still achieved clinically meaningful reductions over the full study period.
According to Novo Nordisk, 28.8% of adults taking semaglutide tablets were classed as early responders, meaning they lost at least 10% of their body weight by week 16. This group achieved 13.2% weight loss at week 16 and went on to record an average weight loss of 21.6% by week 64.
However, the data also showed that those who did not meet the early response threshold still achieved an average weight loss of 11.5% by week 64. That detail is significant because it reinforces a key point in modern obesity care: response can vary, and meaningful outcomes may still develop over time.
A Consultant in Diabetes and Endocrinology in Portsmouth noted that obesity management is not a one-size-fits-all process, but rather a nuanced area of care where individual responses can differ markedly.
The OASIS 4 findings appear to support that view, showing that early results can be helpful but should not always be treated as the only measure of long-term treatment value.
Mobility and Quality of Life Enter the Spotlight
Beyond weight loss alone, Novo Nordisk also reported findings relating to physical function, mobility and bodily pain.
A separate analysis showed that 77.3% of people with poor physical function at baseline experienced clinically meaningful improvements in mobility and bodily pain scores when taking semaglutide tablets. This compared with 42.9% of those receiving placebo.
The weight loss observed in this group was similar to that seen across the overall treatment arm, suggesting that the benefits were not isolated to a narrow subgroup of patients.
For people living with obesity, this may be especially relevant, as the condition can often affect daily movement, comfort, confidence and broader quality of life.
The UK General Manager of Novo Nordisk UK commented that the results are an important reminder that living with obesity can affect much more than body weight alone. It can influence how comfortable people feel moving through their day-to-day lives.
That message reflects a broader shift in how obesity is increasingly discussed across healthcare. The focus is moving beyond the number on the scale and towards the practical realities of living with the condition, including physical function, pain, mobility and overall wellbeing.
Semaglutide Compared with Emerging Competitors
Further findings from the ORION and OPTIC studies, also presented at ECO2026, added another layer to Novo Nordisk’s update.
These studies indicated that semaglutide 25mg tablets delivered greater weight loss than orforglipron 36mg and were associated with lower odds of treatment discontinuation due to gastrointestinal side effects.
In the OPTIC study, 90% of 800 survey respondents preferred a treatment profile similar to semaglutide tablets. For pharmaceutical companies competing in the fast-moving obesity market, patient preference, tolerability and ease of use are becoming increasingly important differentiators.
The new analyses build on the primary OASIS 4 results, which showed that adults taking semaglutide tablets achieved 16.6% average weight loss compared with 2.7% for placebo. Novo Nordisk also reported that the safety profile was consistent with the GLP-1 class.
Taken together, the data strengthens the company’s positioning in the obesity treatment market, particularly as oral options continue to attract attention from patients, clinicians and healthcare systems looking for effective alternatives to injectable medicines.
Enterprise Therapeutics Reports Positive Phase 2 Results in Cystic Fibrosis
While Novo Nordisk’s update focused on obesity care, Enterprise Therapeutics has reported an important milestone in cystic fibrosis treatment.
The company announced that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel blocker, met its primary efficacy outcome in people with cystic fibrosis who do not benefit from CFTR modulators.
This is a particularly high-need patient group. The trial focused on the estimated 10% of people with cystic fibrosis who have the greatest unmet medical need because currently available CFTR modulator therapies do not provide benefit for them.
The study showed clinically meaningful and statistically significant improvements in lung function over 28 days compared with placebo. Enterprise reported a 3.4 percentage point difference in ppFEV1 between ETD001 and placebo, with a p value of 0.0053.
Exploratory analysis also suggested that participants receiving ETD001 were three times more likely to show improvement in ppFEV1.
A New Mechanism with Potential in Respiratory Disease
ETD001 is designed as an inhaled ENaC blocker. By targeting epithelial sodium channels, the treatment aims to improve airway hydration and mucus clearance, which are central challenges in cystic fibrosis.
The company said ETD001 was overall well tolerated, with adverse events consistent with expectations for people with cystic fibrosis receiving inhaled therapies. The study was conducted across sites in the United Kingdom, Germany, France and Italy.
The trial design included two parts. Part A assessed safety and tolerability over seven days, while Part B used a double-blind, placebo-controlled cross-over design to measure the effect of twice-daily dosing over 28 days.
Enterprise Therapeutics’ Chief Medical Officer said the company was delighted to report positive phase 2 results, noting that the novel inhaled ENaC blocker was well tolerated in people with cystic fibrosis and showed improved lung function over a 28-day period compared with placebo.
The company’s Chief Scientific Officer described the data as a critical milestone, stating that it represents the first time an ENaC blocker has demonstrated efficacy in people with cystic fibrosis.
The Chief Executive Officer also thanked those involved in developing the ETD001 programme, adding that it was heartening to see the results from the phase 2 trial.
Next Steps for ETD001
Following the positive data, Enterprise Therapeutics now plans to move towards longer-duration phase 2b studies. These will be important in establishing whether the lung function improvements seen over 28 days can be sustained over a longer treatment period.
The company will also explore ETD001 in non-CF bronchiectasis, broadening the potential relevance of the therapy beyond cystic fibrosis alone. That could become an important strategic step if the drug continues to show benefit in conditions where mucus clearance and airway hydration remain major treatment challenges.
For a smaller biotechnology company, positive phase 2 data can be a defining moment. It can support further investment, partnership discussions and expanded clinical development, particularly when the therapy is addressing a clear area of unmet need.
Impact on Pharmaceutical Manufacturing and Production
These developments also carry important implications for pharmaceutical manufacturing and production.
Novo Nordisk’s oral semaglutide data reflects the growing demand for scalable, convenient GLP-1 therapies, which may increase pressure on tablet manufacturing capacity, supply chain planning, active pharmaceutical ingredient production and quality control systems.
For Enterprise Therapeutics, ETD001 highlights a different manufacturing challenge. Inhaled therapies require precise formulation, device compatibility, particle delivery performance, sterility considerations and consistency across batches.
If ETD001 progresses into larger and longer studies, production processes will need to support clinical scale-up while maintaining strict respiratory drug standards.
Together, the two updates show how pharmaceutical production is being shaped by both high-volume metabolic medicines and highly specialised respiratory treatments.
Manufacturers are being asked to support innovation at both ends of the market: mass-demand medicines for global chronic disease management and targeted therapies for smaller patient populations with significant unmet need.
Mot de la fin
Novo Nordisk and Enterprise Therapeutics have delivered two very different, but equally notable, clinical updates.
Novo Nordisk’s OASIS 4, ORION and OPTIC findings strengthen the case for oral semaglutide as a major player in obesity care, particularly by showing meaningful weight loss, mobility improvements and strong treatment-profile preference.
Enterprise Therapeutics, meanwhile, has reported a potentially important step forward for people with cystic fibrosis who do not benefit from existing CFTR modulators. Its ETD001 data suggests that inhaled ENaC blockade could offer a new route for improving lung function in a group of patients with limited options.
Across both stories, the direction of travel is clear. The pharmaceutical industry is not only chasing bigger clinical outcomes, but also more practical, patient-relevant benefits: movement, comfort, tolerability, lung function and treatment choice.
For patients, clinicians, manufacturers and developers, that makes these updates more than just trial readouts. They are signs of where modern medicine is heading next.
News Credits:
Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
Ce que vous aimeriez peut-être aussi savoir :